Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation.

doi: 10.1016/j.jconrel.2023.04.011

Figure Lengend Snippet: Fig. 1. The schematic illustration of liposome-mediated immunochemotherapy. This figure depicts a schematic representation of liposome-mediated immunoche motherapy. The liposomes (OLP) are shown as spherical structures enclosing therapeutic agents such as the chemotherapeutic drug oxaliplatin (OXA) and the STING agonist ADU-S100. The liposomes are designed to target the tumor cells specifically and facilitate the delivery of the therapeutic agents to the TME. Upon reaching the TME, the liposomes are taken up by the tumor cells and the therapeutic agents are released into the surrounding area. The release of OXA triggers the immunogenic cell death of the tumor cells, which further activates the immune system. Meanwhile, the released ADU-S100 activates the STING pathway, promoting the production of type I interferons and cytokines. This results in the recruitment of immune cells such as DCs, which prime T cells for a specific anti-tumor response. The liposome-mediated immunochemotherapy not only enhances the anti-tumor immune response, but also reduces the recruitment of M2 macrophages and reg ulatory T lymphocytes (Tregs) in the TME. These combined effects of liposome-mediated immunochemotherapy result in a more effective and targeted approach for cancer treatment.

Article Snippet: Oxaliplatin was obtained from EDQM (Strasbourg, France).

Techniques: Liposomes

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation.

doi: 10.1016/j.jconrel.2023.04.011

Figure Lengend Snippet: Fig. 2. The characterization of liposomes. A. TEM (transmission electron microscopy) images of eLP (empty liposomes) and OLP (oxaliplatin-loaded liposomes). B. Size and zeta potential distribution of liposomes. C. In vitro cumulative release behaviors of free oxaliplatin and OLP.

Article Snippet: Oxaliplatin was obtained from EDQM (Strasbourg, France).

Techniques: Liposomes, Transmission Assay, Electron Microscopy, Zeta Potential Analyzer, In Vitro

Journal: Oncogene

Article Title: Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential

doi: 10.1038/onc.2015.48

Figure Lengend Snippet: (A) DOX and carboplatin combination treatment caused tumor stasis, as seen by a significant difference in the growth rate of combination group, compared to all other treatment groups. Arrows point to the time of carboplatin injection. (B) There is a significant decrease in the average change in volume after treatment (n=20 for carboplatin+DOX group, n=15 for DOX only, n=8 for vehicle and carboplatin alone groups) (C–D) AnnexinV FACS analysis shows a significant increase in the number of cells undergoing early stages of apoptosis in the combination treatment group, as compared to all other groups. Sytox red staining represents dead cells, therefore cells positive only for AnnexinV were considered currently undergoing apoptosis. Analysis included only GFP+ or RFP+ cells, therefore AnnexinV positive cells are represented only through these gates, and quantified to the left.

Article Snippet: Carboplatin (MP Biomedicals 198873) was resuspended in 0.9% NaCl and i.p. injected into mice once a week, at a concentration of 50 mg/kg.

Techniques: Injection, Staining